Today’s improvement in asthma treatment: role of MART and Easyhaler


Asthma affects more than 330 million people worldwide, but many analyses have shown that there are still a lot of unmet needs for both patients and physicians in the treatment of asthma: poor adherence to treatment is one of the main causes of sub-optimal clinical results. Maintenance and Reliever Therapy (MART) with the combination of formoterol and inhaled corticosteroids (ICS) has an established scientific rationale and demonstrated to reduce asthma exacerbations. The aim of this review is to highlight how in asthmatic patients MART can be able to express its maximum therapeutic potential when administered through an ‘ideal inhaler’. Since the treatment may be necessary several times a day, the use of a single combination inhaler simplifies the management, potentially improving adherence; moreover, easiness of use and comfort in administration of asthma treatment devices are not secondary aspects. Asthmatic patients are often young, with a normal relational and working life and they could request for a comfortable and not too noticeable device. Finally to the “ideal inhaler” is requested to guarantee accuracy, dose consistency, and resistance to stress conditions. Easyhaler® more closely demonstrates many expected characteristics: effective, consistent performance regardless of inspiration rate, stability, versatility, with several patient acceptability advantages. Asthma control is enhanced by a strong adherence obtained through the combination in a single inhaler of both maintenance and reliever therapy and the availability of a device as close as possible to the characteristics of the ideal inhaler. 



PlumX Metrics


Download data is not yet available.


Croisant S. Epidemiology of asthma: Prevalence and burden of disease. Adv Exp Med Biol 2014;795:17–29. DOI:

Ghaffari J. The prevalence of children’s asthma: A few comments. Clin Respir J 2018;12:2454. DOI:

Global Asthma Network [Internet]. Global Asthma Report 2014. Available from:

To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health 2012;12:204. DOI:

Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, et al. Economic burden of asthma: a systematic review. BMC Pulm Med 2009;9:24. DOI:

Accordini S, Bugiani M, Arossa W, Gerzeli S, Marinoni A, Olivieri M, et al. Poor control increases the economic cost of asthma. A multicentre population-based study. Int Arch Allergy Immunol 2006;141:189–98. DOI:

Hoskins G, McCowan C, Neville RG, Thomas GE, Smith B, Silverman S. Risk factors and costs associated with an asthma attack. Thorax 2000;55:19–24. DOI:

WHO. Aderence to long-term therapies. Evidence for action. Available from:

Partridge MR, van der Molen T, Myrseth S-E, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006;6:13. DOI:

Boulet L-P, Vervloet D, Magar Y, Foster JM. Adherence. Clin Chest Med 2012;33:405-17. DOI:

Beasley R, Braithwaite I, Fingleton J, Weatherall M. The inhaled corticosteroid/long-acting β-agonist maintenance and reliever therapy regimen: where to from here? Eur Respir J 2018;51:1702338. DOI:

O’Byrne PM, Jenkins C, Bateman ED. The paradoxes of asthma management: time for a new approach? Eur Respir J 2017;50:1701103. DOI:

Global Initiative for Asthma – GINA [Internet]. 2020 Global Strategy for Asthma Management and Prevention. Available from:,on%20the%20GINA%20Science%20Committee

O’Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378:1865-76. DOI:

Bateman ED, Reddel HK, O’Byrne PM, Barnes PJ, Zhong N, Keen C, et al. As-needed budesonide–formoterol versus maintenance budesonide in mild asthma. N Engl J Med.2018;378:1877–87. DOI:

Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med 2019;380:2020-30. DOI:

Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet 2019;394:919-28. DOI:

Valero A, Olaguibel J, Delgado J, Plaza V, Álvarez F, Molina J, et al. Re-evolution of asthma management: dilemmas and new paradigms. J Investig Allergol Clin Immunol 2019;29:15-23. DOI:

Plaza Moral V, Alonso Mostaza S, Alvarez Rodríguez C, Gomez-Outes A, Gómez Ruiz F, López Vina A, et al. Spanish guideline on the management of asthma. J Investig Allergol Clin Immunol 2016;26:S1-92.

Reddel HK, Busse WW, Pedersen S, Tan WC, Chen Y-Z, Jorup C, et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet 2017;389:157–66. d DOI:

Haahtela T, Herse F, Karjalainen J, Klaukka T, Linna M, Leskelä R-L, et al. The Finnish experience to save asthma costs by improving care in 1987-2013. J Allergy Clin Immunol 2017;139:408-14.e2. DOI:

O’Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171:129–36. DOI:

Jenkins CR, Bateman ED, Sears MR, O’Byrne PM. What have we learnt about asthma control from trials of budesonide/formoterol as maintenance and reliever? Respirology 2020. doi:10.1111/resp.13804. DOI:

Sobieraj DM, Weeda ER, Nguyen E, Coleman CI, White CM, Lazarus SC, et al. Association of Inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma. JAMA 2018;319:1485. DOI:

Laube BL, Janssens HM, de Jongh FHC, Devadason SG, Dhand R, Diot P, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011;37:1308-417. DOI:

Dal Negro RW. Dry powder inhalers and the right things to remember: a concept review. Multidiscip Respir Med 2015;10:13. doi:10.1186/s40248-015-0012-5. DOI:

Lavorini F, Magnan A, Christophe Dubus J, Voshaar T, Corbetta L, Broeders M, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 2008;102:593-604. DOI:

Virchow JC, Akdis CA, Darba J, Dekhuijzen R, Hartl S, Kobelt G, et al. A review of the value of innovation in inhalers for COPD and asthma. J Mark Access Health Policy 2015;3:28760. DOI:

Vidgren M, Silvasti M, Vidgren P, Sormunen H, Laurikainen K, Korhonen P. Easyhaler® multiple dose powder inhaler - Practical and effective alternative to the pressurized MDI. Aerosol Sci Technol 1995;22:335–45. DOI:

Lavorini F. Easyhaler®: An overview of an inhaler device for day-to-day use in patients with asthma and chronic obstructive pulmonary disease. Drugs Context 2019;8:212596. DOI:

Clark Ar, Hollingworth Am. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers — Implications for in vitro testing. J Aerosol Med 1993;6:99–110. DOI:

Valero A, Ribó P, Maíz L, Barbero E, Calle M, Campo C, et al. Asthma patient satisfaction with different dry powder inhalers. Expert Rev Respir Med 2019;13:133–8. DOI:

De Blaquiere P, Christensen DB, Carter WB, Martin TR. Use and misuse of metered-dose inhalers by patients with chronic lung disease. A controlled, randomized trial of two instruction methods. Am Rev Respir Dis 1989;140:910–6. DOI:

Tamási L, Szilasi M, Gálffy G. Clinical effectiveness of budesonide/formoterol fumarate Easyhaler® for patients with poorly controlled obstructive airway disease: a real-world study of patient-reported outcomes. Adv Ther 2018;35:1140–52. DOI:

Schweisfurth H, Malinen A, Koskela T, Toivanen P, Ranki-Pesonen M, German Study Group. Comparison of two budesonide powder inhalers, Easyhaler and Turbuhaler, in steroid-naïve asthmatic patients. Respir Med 2002;96:599–606. DOI:

Lahelma S, Kirjavainen M, Kela M, Herttuainen J, Vahteristo M, Silvasti M, et al. Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method. Br J Clin Pharmacol 2005;59:167–73. DOI:

Hämäläinen KM, Granander M, Toivanen P, Malinen A. Assessment of the systemic effects of budesonide inhaled from Easyhaler and from Turbuhaler in healthy male volunteers. Respir Med. 2001;95:863–9. DOI:

Tukiainen H, Rytilä P, Hämäläinen KM, Silvasti MSL, Keski-Karhu J, Finnish Study Group. Safety, tolerability and acceptability of two dry powder inhalers in the administration of budesonide in steroid-treated asthmatic patients. Respir Med. 2002;96:221–9. DOI:

Vanto T, Hämäläinen KM, Vahteristo M, Wille S, Njå F, Hyldebrandt N, et al. Comparison of two budesonide dry powder inhalers in the treatment of asthma in children. J Aerosol Med. 2004;17:15–24. DOI:

Lähelmä S, Vahteristo M, Metev H, Taseva M, Stamatova N, Bartha A, et al. Equivalent bronchodilation with budesonide/formoterol combination via Easyhaler and Turbuhaler in patients with asthma. Respir Med 2016;120:31–5. DOI:

Haikarainen J, Selroos O, Löytänä T, Metsärinne S, Happonen A, Rytilä P. Budesonide/formoterol Easyhaler®: Performance under simulated real-life conditions. Pulm Ther 2017;3:125–38. DOI:

Giner J, Torrejón M, Ramos A, Casan P, Granel C, Plaza V, et al. [Patient preference in the choice of dry powder inhalers].[Article in Spanish]. Arch Bronconeumol 2004;40:106–9. DOI:

Nsour WM, Alldred A, Corrado J, Chrystyn H. Measurement of peak inhalation rates with an in-check meter to identify an elderly patient’s ability to use a turbuhaler. Respir Med 2001;95:965–8. DOI:

Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. EDICI. Respir Med 2000;94:496–500. DOI:

Jäger L, Laurikainen K, Leinonen M, Silvasti M. Beclomethasone dipropionate Easyhaler is as effective as budesonide Turbohaler in the control of asthma and is preferred by patients. German Study Group. Int J Clin Pract 54:368–72.

Rönmark E, Jögi R, Lindqvist A, Haugen T, Meren M, Loit H, et al. Correct use of three powder inhalers: comparison between Diskus, Turbuhaler, and Easyhaler. J Asthma 2005;42:173–8. DOI:

Syk J, Vinge I, Sörberg M, Vahteristo M, Rytilä P. A multicenter, observational, prospective study of the effectiveness of switching from budesonide/formoterol Turbuhaler® to budesonide/formoterol Easyhaler®. Adv Ther 2019;36:1756–69. DOI:

Rytilä P, Syk J, Vinge I SM. Switch from Symbicort Turbuhaler to Bufomix Easyhaler; a real-life prospective study in asthma patients. Eur Resp J 2018;52:PA3998. DOI:

Selroos O, Löfroos AB, Pietinalho A, Riska H. Comparison of terbutaline and placebo from a pressurised metered dose inhaler and a dry powder inhaler in a subgroup of patients with asthma. Thorax 1994;49:1228–30. DOI:

Chrystyn H. Closer to an “ideal inhaler” with the Easyhaler®: An innovative dry powder inhaler. Clin Drug Investig 2006;26:175–83. DOI:

Chrystyn H, Haahtela T. Real-life inhalation therapy – Inhaler performance and patient education matter. Eur Respir Dis 2012;8:11–8.

Asthma, treatment adherence and compliance, anti-asthmatic agents, budesonide formoterol fumarate drug combination, inhalation device
  • Abstract views: 1145

  • PDF: 307
  • HTML: 0
How to Cite
Di Marco, F. (2020). Today’s improvement in asthma treatment: role of MART and Easyhaler. Multidisciplinary Respiratory Medicine, 15.